Tokyo-headquartered pharma major Takeda has announced results for the first half of its fiscal year, which in Japan runs from 1 April to 1 September. 27 October 2023
Eisai and Biogen have announced the presentation of new data for their Alzheimer’s drug Leqembi (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use. 26 October 2023
US pharma giant Merck & Co has opted to pull the plug on two mid-stage trials of Alzheimer’s disease candidate MK-1942, due to safety worries. 26 October 2023
After scientific advisors recommended that the US regulator not approve a new amyotrophic lateral sclerosis (ALS) therapy, developer BrainStorm Cell Therapeutic 19 October 2023
Israeli drugmaker Teva Pharmaceutical Industries has announced that data from the UNITE study presented at the World Congress of Neurology in Montreal, Canada, 17 October 2023
In the USA, the National Institutes of Health has outlined significant new investments to support research into amyotrophic lateral sclerosis (ALS). 10 October 2023
California-based Vistagen Therapeutics, a company aiming to transform the treatment landscape for anxiety, depression, and other central nervous system (CNS) di 4 October 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.